16 results match your criteria: "Tampa General Hospital Cancer Institute[Affiliation]"
Semin Hematol
December 2024
Tampa General Hospital Cancer Institute, Tampa, FL, USA. Electronic address:
Background Chimeric antigen receptor T-cell (CAR-T) therapy offers a promising treatment for certain malignancies but can be associated with complications. Malnutrition and cachexia are common in cancer patients and may worsen outcomes. This study investigated the impact of malnutrition on the length of hospital stay (LOS) in patients with hematologic malignancies undergoing CAR-T therapy.
View Article and Find Full Text PDFJAMA Oncol
December 2024
University of Toronto, Toronto, Ontario, Canada.
J Appl Clin Med Phys
November 2024
Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix, Arizona, USA.
Int J Radiat Oncol Biol Phys
July 2024
Department of Medical Oncology, Tampa General Hospital Cancer Institute, Tampa, Florida.
A 67-year-old female came to Tampa General Hospital with Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) featuring an intriguing combination of mutations, including and mutations. Novel combination therapy with azacitidine, venetoclax and ponatinib allowed her to successfully achieve a complete response (CR) and undergo an allogeneic hematopoietic stem cell transplant (HSCT). This case report provides an overview of her clinical course, emphasizing the significance of integrated therapy and the challenges associated with balancing treatment for AML.
View Article and Find Full Text PDFJ Occup Environ Med
June 2024
From the College of Nursing, University of South Florida, Tampa, Florida (J.K., B.P., M.E., U.M.); College of Public Health, University of South Florida, Tampa, Florida (A.G.); Morsani College of Medicine, University of South Florida, Tampa, Florida (L.S., N.A.); National Institute for Public Safety Health, Ascension Public Safety Medical, Indianapolis, Indiana (S.M.M., C.M.M.); University of Arizona Comprehensive Cancer Center, Tucson, Arizona (D.C.); and Tampa General Hospital Cancer Institute, Tampa, Florida (J.K., N.A., U.M.).
Objective: Firefighters are at increased risk of colorectal cancer (CRC), yet rates of CRC screening are low among this occupational group. This study examines perceived risks, barriers, and facilitators to CRC screening.
Methods: Three semistructured focus group discussions were conducted by investigators in Tucson, AZ.
Cancer
May 2024
Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA.
Management of venous thromboembolism (VTE) in patients with primary and metastatic brain tumors (BT) is challenging because of the risk of intracranial hemorrhage (ICH). There are no prospective clinical trials evaluating safety and efficacy of direct oral anticoagulants (DOACs), specifically in patients with BT, but they are widely used for VTE in this population. A group of neuro-oncology experts convened to provide practical clinical guidance for the off-label use of DOACs in treating VTE in patients with BT.
View Article and Find Full Text PDFbioRxiv
August 2023
Johns Hopkins University School of Medicine, Bloomberg Kimmel Institute for Cancer Immunotherapy.
Immunotherapy is now an integral aspect of cancer therapy. Strategies employing adoptive cell therapy (ACT) have seen the establishment of chimeric antigen receptor (CAR)-T cells using peripheral blood lymphocytes as well as tumor infiltrating lymphocytes (TILs) with significant clinical results. Despite these successes, the limitations of the current strategies are also emerging and novel approaches are needed.
View Article and Find Full Text PDFCancer Cell
September 2023
Institute for Systems Genetics, NYU Grossman School of Medicine, New York, NY 10016, USA; Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY 10016, USA. Electronic address:
We characterized a prospective endometrial carcinoma (EC) cohort containing 138 tumors and 20 enriched normal tissues using 10 different omics platforms. Targeted quantitation of two peptides can predict antigen processing and presentation machinery activity, and may inform patient selection for immunotherapy. Association analysis between MYC activity and metformin treatment in both patients and cell lines suggests a potential role for metformin treatment in non-diabetic patients with elevated MYC activity.
View Article and Find Full Text PDFLeuk Res
August 2023
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address:
BMC Womens Health
June 2023
Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1330, Houston, TX, 77030, USA.
Background: The Hispanic population is heterogeneous with differences in health behaviors across subgroups by nativity and preferred language. We evaluated cervical cancer screening adherence among English- and Spanish-speaking Hispanic patients receiving care at a safety net health system.
Methods: Electronic health records were used to identify 46,094 women aged 30-65.
BMC Cancer
March 2022
Department of Surgery & Molecular Medicine, University of South Florida, Tampa General Hospital Cancer Institute, 560 Channelside Drive, Tampa, FL, 33602, USA.
Background: Over half of colorectal cancers (CRCs) are hard-wired to RAS/RAF/MEK/ERK pathway oncogenic signaling. However, the promise of targeted therapeutic inhibitors, has been tempered by disappointing clinical activity, likely due to complex resistance mechanisms that are not well understood. This study aims to investigate MEK inhibitor-associated resistance signaling and identify subpopulation(s) of CRC patients who may be sensitive to biomarker-driven drug combination(s).
View Article and Find Full Text PDFClin Genitourin Cancer
June 2022
University of South Florida Morsani College of Medicine, Department of Internal Medicine, Tampa, FL; Tampa General Hospital Cancer Institute, Genitourinary Oncology, Tampa, FL. Electronic address:
Introduction: The ligation of the interleukin-2 (IL-2) receptor and immune checkpoint blockade may each alter lymphocytes, thereby inducing regression in various cancers. Single agent objective response rates of 14% to 25% have been reported for usual schedule 14-dose-in-a-row IL-2 therapy of metastatic clear cell renal cancer (ccRCC), with a notable subset of responses being durable. Pembrolizumab yielded a 33% response rate in patients with metastatic ccRCC.
View Article and Find Full Text PDFAm J Hematol
May 2022
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Leukemia
April 2022
Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.